Future directions include immunohistochemical confirmation of MIF-CD74, APP-CD74, and CXCL12–CXCR4 interactions between pRMS tumor and immune cells and testing of the MIF and APP inhibition effect on pRMS in vitro and in vivo. The gene discussed is CXCR4; the disease is neoplasm.